Literature DB >> 29632217

Projected Costs of Informal Caregiving for Cardiovascular Disease: 2015 to 2035: A Policy Statement From the American Heart Association.

Sandra B Dunbar, Olga A Khavjou, Tamilyn Bakas, Gail Hunt, Rebecca A Kirch, Alyssa R Leib, R Sean Morrison, Diana C Poehler, Veronique L Roger, Laurie P Whitsel.   

Abstract

INTRODUCTION: In a recent report, the American Heart Association estimated that medical costs and productivity losses of cardiovascular disease (CVD) are expected to grow from $555 billion in 2015 to $1.1 trillion in 2035. Although the burden is significant, the estimate does not include the costs of family, informal, or unpaid caregiving provided to patients with CVD. In this analysis, we estimated projections of costs of informal caregiving attributable to CVD for 2015 to 2035.
METHODS: We used data from the 2014 Health and Retirement Survey to estimate hours of informal caregiving for individuals with CVD by age/sex/race using a zero-inflated binomial model and controlling for sociodemographic factors and health conditions. Costs of informal caregiving were estimated separately for hypertension, coronary heart disease, heart failure, stroke, and other heart disease. We analyzed data from a nationally representative sample of 16 731 noninstitutionalized adults ≥54 years of age. The value of caregiving hours was monetized by the use of home health aide workers' wages. The per-person costs were multiplied by census population counts to estimate nation-level costs and to be consistent with other American Heart Association analyses of burden of CVD, and the costs were projected from 2015 through 2035, assuming that within each age/sex/racial group, CVD prevalence and caregiving hours remain constant.
RESULTS: The costs of informal caregiving for patients with CVD were estimated to be $61 billion in 2015 and are projected to increase to $128 billion in 2035. Costs of informal caregiving of patients with stroke constitute more than half of the total costs of CVD informal caregiving ($31 billion in 2015 and $66 billion in 2035). By age, costs are the highest among those 65 to 79 years of age in 2015 but are expected to be surpassed by costs among those ≥80 years of age by 2035. Costs of informal caregiving for patients with CVD represent an additional 11% of medical and productivity costs attributable to CVD.
CONCLUSIONS: The burden of informal caregiving for patients with CVD is significant; accounting for these costs increases total CVD costs to $616 billion in 2015 and $1.2 trillion in 2035. These estimates have important research and policy implications, and they may be used to guide policy development to reduce the burden of CVD on patients and their caregivers.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  AHA Scientific Statements; cardiovascular diseases; caregivers; cost of illness

Mesh:

Year:  2018        PMID: 29632217     DOI: 10.1161/CIR.0000000000000570

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  47 in total

Review 1.  Recent updates on novel therapeutic targets of cardiovascular diseases.

Authors:  Muhammad Afzal
Journal:  Mol Cell Biochem       Date:  2020-08-26       Impact factor: 3.396

2.  Caregiver subjective and physiological markers of stress and patient heart failure severity in family care dyads.

Authors:  Julie T Bidwell; Camelia E Hostinar; Melinda K Higgins; Martha A Abshire; Fawn Cothran; Brittany Butts; Andrew H Miller; Elizabeth Corwin; Sandra B Dunbar
Journal:  Psychoneuroendocrinology       Date:  2021-08-28       Impact factor: 4.905

3.  Tetrahydroberberrubine retards heart aging in mice by promoting PHB2-mediated mitophagy.

Authors:  Lei Wang; Xue-Qing Tang; Yang Shi; Hui-Min Li; Zi-Yu Meng; Hui Chen; Xiao-Han Li; Yong-Chao Chen; Heng Liu; Yang Hong; Heng-Hui Xu; Ling Liu; Limin Zhao; Wei-Na Han; Xin Liu; Yong Zhang
Journal:  Acta Pharmacol Sin       Date:  2022-08-10       Impact factor: 7.169

4.  The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022.

Authors:  Xia Xu; Yumeng Li; Shuqing Shi; Jiayu Lv; Yajiao Wang; Haoran Zheng; Xinxin Mao; Huaqin Wu; Bingxuan Zhang; Qingqiao Song
Journal:  Front Cardiovasc Med       Date:  2022-05-04

Review 5.  Role of Palliative Care in the Outpatient Management of the Chronic Heart Failure Patient.

Authors:  Sarah Chuzi; Esther S Pak; Akshay S Desai; Kristen G Schaefer; Haider J Warraich
Journal:  Curr Heart Fail Rep       Date:  2019-12

6.  Down-regulation of MEIS1 promotes the maturation of oxidative phosphorylation in perinatal cardiomyocytes.

Authors:  Isa M Lindgren; Rachel R Drake; Natasha N Chattergoon; Kent L Thornburg
Journal:  FASEB J       Date:  2019-03-18       Impact factor: 5.191

7.  Clinical and Economic Burden of Stroke Among Young, Midlife, and Older Adults in the United States, 2002-2017.

Authors:  Safi U Khan; Muhammad Zia Khan; Muhammad U Khan; Muhammad Shahzeb Khan; Mamas A Mamas; Muhammad Rashid; Ron Blankstein; Salim S Virani; Michelle C Johansen; Michael D Shapiro; Michael J Blaha; Miguel Cainzos-Achirica; Farhaan S Vahidy; Khurram Nasir
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-04-08

8.  Activation of Neuropeptide Y2 Receptor Can Inhibit Global Cerebral Ischemia-Induced Brain Injury.

Authors:  Reggie Hui-Chao Lee; Celeste Yin-Chieh Wu; Cristiane T Citadin; Alexandre Couto E Silva; Harlee E Possoit; Garrett A Clemons; Christina H Acosta; Victoria A de la Llama; Jake T Neumann; Hung Wen Lin
Journal:  Neuromolecular Med       Date:  2021-05-21       Impact factor: 4.103

9.  Engaging Families in Adult Cardiovascular Care: A Scientific Statement From the American Heart Association.

Authors:  Michael J Goldfarb; Christine Bechtel; Quinn Capers; Ann de Velasco; John A Dodson; Jamie L Jackson; Lisa Kitko; Ileana L Piña; Erin Rayner-Hartley; Nanette K Wenger; Martha Gulati
Journal:  J Am Heart Assoc       Date:  2022-04-21       Impact factor: 6.106

10.  Advance Care Planning Documentation and Intensity of Care at the End of Life for Adults With Congestive Heart Failure, Chronic Kidney Disease, and Both Illnesses.

Authors:  Gwen M Bernacki; Cara L McDermott; Daniel D Matlock; Ann M O'Hare; Lyndia Brumback; Nisha Bansal; James N Kirkpatrick; Ruth A Engelberg; Jared Randall Curtis
Journal:  J Pain Symptom Manage       Date:  2021-08-04       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.